"WE ARE STUCK WITH TECHNOLOGY WHEN WHAT WE REALLY WANT IS JUST STUFF THAT WORKS." -DOUGLAS ADAMS

Eplet Matching - Kidney Now or Later

Nicole M Valenzuela, PhD, D(ABHI)

Department of Pathology and Laboratory Medicine, University of California, Los Angeles




• HLA eplets

an Founda

- Premise
- State of field
- Potential application
- Health Disparities

Overview




Structure and Polymorphism of HLA

• HLA molecules present peptides to T cells


- HLA class I is formed by a continuous polypeptide encoded by one gene
 - Expressed on every nucleated cell
- HLA class II proteins are heterodimers formed by the gene products of alpha (α) and beta (β) genes
 - Only expressed on antigen presenting cells and activated/inflamed cells like endothelium




Numbers of HLA AllelesHLA Class I Alleles25,228HLA Class II Alleles10,592




Sources of HLA Allosensitization




Evolution of HLA Typing and Compatibility




Association of antigen level mismatching with outcome








Degrees of difference





Degrees of difference




What are HLA Eplets?

HLA eplets are amino acid residues that are different between two alleles, that *may* represent a target for an antibody or T cell





HLA Eplet vs. Antigen Mismatching




Clinical Utility of HLA Eplet Mismatching



14th Annual Living Donation Conference


HLA Eplet Mismatching: Keep in mind



Multiple algorithms

- Some in silico, others based on antibody verification
- Literature is a mix of approaches
- No consensus yet on which is the "best"








Requires high resolution typing

- Can be imputed from intermediate but imperfect accuracy, especially in non-Europeans [Engen AJT 2021]
- Larger studies from SRTR are based on imputation

Thresholds and relative risk are not fully defined

- How many is too many?
- Which mismatches are worse?
- Which outcome is more important?


Clinical Utility of HLA Eplet Mismatching



14th Annual Living Donation Conference

Improving access to transplant

Pre-transplant



- equitable access
- DSA cross-reactivity
- unacceptable antigen


<u>chance of finding a compatible donor</u> for highly sensitized patients based on 0-2 triplet mismatches was much higher compared to matching on the antigen level [Duquesnoy *Transpl* 2003]

<u>reduced transplant wait time</u> for highly sensitized patients by 50% with comparable outcomes as non-sensitized patients [Eurotransplant; Lemieux Int Immuno 2021; Heidt Transpl 2019]

eplet based method of antibody analysis had a very high degree of <u>correlation</u> <u>with cell-based crossmatches</u> [Norin *Hum Immun* 2022]



Improving post-transplant outcomes



DR or DQ eplet mismatch was significantly correlated with production of **dnDSA** to that locus (OR 2.50 and 2.00 per 10MM) [Wiebe JASN 2017]

antibody-verified eplet mismatch load was associated with any type of **rejection**; but no threshold below which the risk of dnDSA occurrence was absent [Senev JASN 2020]

low-immunological risk recipients (0-2 ABDR mismatched kidneys) but with high eplet mismatches (≥20) had 2-fold increased <u>risk of acute</u> <u>rejection</u> [Nguyen *Transpl Dir* 2016]


significant relationship between eplet mismatches and graft failure; greater effect in unsensitized recipients [Sapir-Pichhadze Kid Int 2020]

discriminative performance for graft failure was low [Senev JASN 2020]

after dnDSA development in kidney transplant recipients, eplet mismatches did not correlate with ABMR or allograft loss [Wen Hum Immun 2021]

Tailoring immunosuppression based on risk

Post-transplant



 immunosuppression optimization in CTOT-09 DQ mMM (>17) predicted dnDSA on <u>TAC minimization</u> despite patients being "low risk" (per sensitization) first 6 months post-transplant [Hricik JASN 2015]

recipients with high eplet mismatch load were <u>less likely to tolerate low</u> <u>tacrolimus</u> levels without developing de novo DSAs [Davis *AJT* 2021]

patients with high-risk DQ eplet mismatch score more frequently developed acute rejection, even if no pre-formed T cell alloimmunity was detected [Bestard AJT 2021]



Proposed Risk Stratification Model

Pretransplant donor-recipient HLA laboratory evaluation							
CDC crossmatch	Flow crossmatch	Single antigen bead	History of sensitization	HLA molecular MM	HLA identical	Immune risk assessment	
DSA positive	DSA positive	DSA positive		a body of evid		Active memory and at risk for hyperacute rejection	
Negative	DSA positive	DSA positive		f the utility of re as a basis fo		Active memory and at risk for ABMR and TCMR	
Negative	Negative	DSA positive	primary a	lloimmunity r	-	Active memory and at risk for ABMR and TCMR	
Negative	Negative	Negative	Pregnancy or pri Stratificat repeat MM	ion"		At risk for latent memory with recall B and T cell response	
Negative	Negative	Negative	cPRA with unknown repeat MM			Potential risk for latent memor with a recall B and T cell response	
Negative	Negative	Negative	No	High		Increased risk for de novo alloimmune response	
Negative	Negative	Negative	No	Low		Baseline risk for de novo alloimmune response	
Negative	Negative	Negative	No	0	Yes	Low risk for de novo alloim- mune response	

MM, Mismatch; DSA, donor-specific antibody; ABMR, antibody-mediated rejection; TCMR, T cell-mediated rejection.



STAR (Tambur AJT 2018; 2019) 14th Annual Living Donation Conference

Proposed prognostic and predictive biomarker for clinical trials (under review by FDA)

The FDA Center for Drug Evaluation and Research agreed to evaluate the potential role of HLA-DR/DQ eplet mMM score as a strategy for **enrichment or risk stratification** in phase 2 and 3 kidney transplant clinical drug development trials and as a **prognostic biomarker** for de novo DSA, graft rejection, and graft failure.


Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development

METHODS

596 renal transplant recipients

- 50,011 serial tacrolimus trough levels
- HLA-DR/DQ eplet mismatch determined using HLAMatchmaker software
- The frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and the mean tacrolimus levels prior to *dn*DSA development were analyzed in the context of HLA-DR/DQ eplet mismatch

OUTCOME Risk of *de novo* DSA development was effected by HLA-DR/DQ eplet Mismatch and tacrolimus trough levels



CONCLUSIONS HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of *dn*DSA development. Recipients with high HLA alloimmune risk should not target tacrolimus levels <5 ng/ml unless essential and monitoring for *dn*DSA may be advisable in this setting.


Crist Wiebs, David Rush, Thomas Newina, Patricia Bris, Tom Blych-Hanson, Lam Globon, Anava Dickberg, Julie Ha, Matrin Karpinski, Domas Pochnoo, AuJ Sharma, Lency Storotegi, Arthur Malas and Piter Nickenson Classis & Eginet Hismarch Michaelses Tarotophisms Trough Lewins Required to Prevent Donor-dipediate Artiblioty Development Judio XdD 2015/01/2011 articles 1061/01/2012/017





14th Annual Living Donation Conference

Decreasing breadth of sensitization after graft failure



highly sensitized patients had <u>lower</u> rates of re-transplantation, and higher rates of nephrectomy/graft intolerance syndrome [Singh *Clin Transpl* 2016]

after graft failure, <u>non-European</u> <u>recipients have a greater cPRA</u> than those of European ancestry [Tambur *Kid Int* 2021]



Decreasing breadth of sensitization after graft failure

-X-WAITLIST

Retransplant


• cPRA after graft failure

clear relationship between the immunogenicity of donor HLA class I and class II mismatches and the development of HLA-specific antibodies <u>after graft failure and</u> <u>relisting for transplantation</u> [Kosmoliaptsis *AJT* 2016]

molecular mismatch scores were independently associated with degree of **sensitization after graft failure** [Kosmoliaptsis *AJT* 2016]

HLA eplet mismatch burden associated with higher risk of higher cPRA after renal allograft failure [Singh Clin Transpl 2016]

Equitable allocation and addressing health disparities



Actual difference Difference after elimination of HLA-B matching Difference after elimination of HLA-B and DR matching -33 -35-Difference in Transplantation Rate (%) -30 -27 -27 -26 -25 -20 -20 -20--15 -10 -5 Blacks vs. Asians vs. Other Races vs. Hispanics vs. Whites Whites Whites Non-Hispanics

Roberts NEJM2004

Table 4. Actual Number of Graft Failures in 2000 and Number Expected If Matching for HLA-B Alone or HLA-B and DR Was No Longer a Priority.*

Race	Actual No. of Graft Failures	Change Resulting from Elimination of HLA-B Matching	Change Resulting from Elimination of HLA-B and DR Matching		
		no. of failures			
All	1779	+36	+142		
White	1057	+21	+85		
Black	631	+13	+51		
Other	91	+2	+7		


* Calculations are based on random matching of donors and recipients with compatible blood types. The rates are for graft failures occurring in 2000 after transplantation between March 6, 1995, and June 30, 2001. The average duration of follow-up was 2.7 years. One- and three-year rates of graft survival for the entire group were 87.2 percent and 77.1 percent, respectively. The relative risk of graft failure was 1.02 (P<0.001) with the elimination of HLA-B matching as a priority and 1.08 (P<0.001) with the elimination of HLA-B and DR matching as a priority, as compared with keeping the current allocation policy.

Bekbolsynov Front Immun 2022

Higher rates of antigen-level mismatching in non-European recipients Models eliminating antigen-level matching predicted increased rates of transplantation for non-European ancestry patients ...but quite offset by greater risk of rejection

Enhancing HLA matching for non-European patients

Pre-transplant



- · equitable access
- DSA cross-reactivity
- unacceptable antigen



the current allocation system inadvertently <u>matches Black patients to</u> <u>donors with significantly higher immunogenic transplants</u> compared to other races


Post-transplant

rejection risk
dnDSA risk
graft longevity

using <u>race-adjusted immunogenicity thresholds</u> in allocation would result in a net gain of thousands additional kidney life-years for all races [Bekbolsynov *Front Immun* 2022]

HLA class I eplet load greater than 70 resulted in a greater risk of rejection in the race-mismatched pediatric transplants vs. race-matched [Philogene *Ped Nephrol* 2019]

Selecting a "better matched" mismatched donor




Practical Applications of HLA Eplet Mismatching



14th Annual Living Donation Conference

Epitopes for Antibody Analysis: Unacceptable Antigen Entry and VXM



Eplets for Allocation?



NATIONAL KIDNEY REGISTRY®

FACILITATING LIVING DONOR TRANSPLANTS

Precise Technology to Find You the Best Match

Surviv 6'0

8.0 E

dnDSA

g

HLA-DR

0.7

0.5

0.4

0


Low Risk

High Risk

Intermediate Risk


2

Traditionally, transplant matches were measured by an HLA match score from 0-6 (6 being the best). HLA scores are generally based on A, B and DR antigens. An antigen mismatch is where rejection often starts.



Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary By minimizing eplet mismatches and understanding the match they receive, a recipient can potentially:

a) reduce the risk of de novo DSA formation
b) lower the probability of rejection
c) lower the probability of graft failure
d) lower their immune-suppression dosage



NKR is currently employing high-

Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant. 2019;19:1708–1719.

0.6 - HLA-DR/DQ Molecular Mismatch Risk Categories

(n=166)

(n=237)

n=261

Follow-up (years)

Presented by the American Foundation for Donation and Transplantation


ion Conference

p<0.0001

p=0.004

p<0.0001

Current Consensus on HLA eplet mismatching



2019 Working Group Meeting Report

1. Approaches need to be optimized and algorithms standardized and locked before implementation in clinical practice.

2.Thresholds for risk categories need to be established and the impact of other factors on these thresholds need to be accounted for. Formal evaluation, in prospective clinical trials, should be performed.


3.Tools to prospectively determine donor/recipient HLA specific **immunogenicity** beyond the mismatch load (given that DSA can be developed in some patients with low HLA mMM score) should be developed.

4.This is essential before considering evaluation and implementation of immunogenicity analysis as a guide to organ allocation schemes.

Takeaways

AR Tambur et al.: Time to reevaluate HLA-DQ matching in transplantation


review



Future Applications:

- Individualized immunologic risk assessment in subpopulations to achieve maximum survival benefit
 - Highly sensitized
 - Pediatric/allograft longevity
- Equitable allocation
- Desensitization efficacy
- Optimization of immunosuppression for retransplant candidates

Figure 3 | The vicious cycle of human leukocyte antigen (HLA) mismatched transplantation and antibody-mediated rejection (ABMR). Ignoring HLA mismatching may expedite receiving the first kidney transplantation, but also puts patients at an increased risk of developing *de novo* donor-specific antibody (DSA), episodes of ABMR, adverse effects from intensified immunosuppression, graft failure, return to dialysis, and prolonged wait time as sensitized patients. Consequences on both the patient and society are listed. cPRA, calculation panel-reactive antibody.



Douglas Adams

Thank you Questions?



14th Annual Living Donation Conference

Extra Information



14th Annual Living Donation Conference

Excellent Reviews

<u>https://www.sciencedirect.com/science/article/pii/S01988859210</u>
 <u>02925</u>



14th Annual Living Donation Conference

Evidence for Clinical Utility

Application	Correlation	Reference
Predict dnDNA risk	DR or DQ eplet mismatch was significantly correlated with production of dnDSA to that locus (OR 2.50 and 2.00 per 10MM) There was <u>no threshold</u> below which the risk of dnDSA occurrence was absent	Wiebe JASN 2017 Senev JASN 2020
Identify compatible donors for highly sensitized candidates	Reduced transplant wait time by 50% with comparable outcomes as non-sensitized patients	Eurotransplant; Lemieux Int Immuno 2021; Heidt Transpl 2019
Predict graft loss	Graft survival comparable 0-2 triplet mismatch recipient and 0 AB antigen mismatches 1.23-1.41 HR per 10 MM	Eurotransplant Sapir-Pichhadze Kid Int 2020
Predict rejection risk	primarily eplet mismatch load on the DQ molecule (OR 1.06) discriminative performance for graft failure was low	Senev JASN 2020
Risk of rejection after dnDSA formed?	once a patient has developed de novo DSA, eplet mismatches <u>did not correlate</u> with ABMR or death- censored allograft loss	WenHum Immun 2021
Breadth of sensitization after graft failure	HLA eplet mismatch burden associated with higher risk of higher cPRA after renal allograft failure	Kosmoliaptsis AJT 2016 Singh Clin Transpl 2016
Risk stratification and/or biomarker in clinical trials	FDA agreed to evaluate DR-DQ eplet mMM score for enrichment or risk stratification in phase 2 and 3 transplant clinical trials and as a prognostic biomarker for de novo DSA, graft rejection, and graft failure.	Wiebe AJT 2019

Session Survey

Nicole Valenzuela, PhD, Suzanne McGuire, RN, BSN, CCTC, and David Serur, MD | April 20th 8:45 AM-9:30 AM





n Found.